DOUGLAS’ SB 77 ESTABLISHING IBOGAINE RESEARCH FRAMEWORK PASSES GENERAL ASSEMBLY, HEADS TO GOVERNOR’S DESK
FRANKFORT, Ky. (April 1, 2026) — The Kentucky General Assembly has passed Senate Bill 77, legislation sponsored by Sen. Donald Douglas, R-Nicholasville, to establish a research framework for ibogaine-based treatments. The measure now heads to the governor’s desk for consideration.
Senate Bill 77 creates a structured pathway for Kentucky to explore the clinical potential of ibogaine in treating opioid use disorder and other substance use disorders, with future applications for conditions such as post-traumatic stress disorder, traumatic brain injury and additional neurological or mental health challenges.
The legislation allows the commonwealth to partner with qualified drug developers conducting FDA-approved clinical trials, while establishing clear standards for patient safety, transparency and regulatory oversight.
“This legislation takes a responsible, science-driven approach to exploring new treatment options for addiction and mental health challenges,” Douglas said. “We’re creating a framework that prioritizes patient safety while allowing Kentucky to be part of cutting-edge medical research that could save lives.”
Douglas said the bill reflects the need to pursue innovative solutions as communities continue to grapple with the impact of addiction.
“Kentucky families know the toll addiction takes, and we cannot afford to ignore emerging therapies that show real promise,” Douglas said. “This framework ensures we can study these treatments carefully, responsibly and with the highest standards in place.”
Senate Bill 77 now heads to the governor’s desk for his signature.